z-logo
Premium
Sensitization to reactive diluents and hardeners in epoxy resin systems. IVDK data 2002–2011. Part I : reaction frequencies
Author(s) -
Geier Johannes,
Lessmann Holger,
Hillen Uwe,
Skudlik Christoph,
Jappe Uta
Publication year - 2016
Publication title -
contact dermatitis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.524
H-Index - 96
eISSN - 1600-0536
pISSN - 0105-1873
DOI - 10.1111/cod.12491
Subject(s) - diluent , sensitization , epoxy , chemistry , immunology , medicine , organic chemistry
Summary Background Epoxy resin systems ( ERS s), consisting of resins, reactive diluents, and hardeners, are indispensable in many branches of industry. In order to develop less sensitizing ERS formulations, knowledge of the sensitizing properties of single components is mandatory. Objectives To analyse the frequency of sensitization in the patients concerned, as one integral part of a research project on the sensitizing potency of epoxy resin compounds ( FP ‐0324). Methods A retrospective analysis of data from the I nformation N etwork of D epartments of D ermatology ( IVDK ), 2002–2011, and a comparison of reaction frequencies with (surrogate) exposure data, were performed. Results Almost half of the patients sensitized to epoxy resin were additionally sensitized to reactive diluents or hardeners. Among the reactive diluents, 1,6‐hexanediol diglycidyl ether was the most frequent allergen, followed by 1,4‐butanediol diglycidyl ether, phenyl glycidyl ether, and p ‐tert‐butylphenyl glycidyl ether. Among the hardeners, m ‐xylylene diamine ( MXDA ) and isophorone diamine ( IPDA ) were the most frequent allergens. According to the calculated exposure‐related frequency of sensitization, MXDA seems to be a far more important sensitizer than IPDA . Up to 60% of the patients sensitized to hardeners and 15–20% of those sensitized to reactive diluents do not react to epoxy resin. Conclusions In cases of suspected contact allergy to an ERS , a complete epoxy resin series must be patch tested from the start.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here